[go: up one dir, main page]

AR062575A1 - Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol - Google Patents

Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol

Info

Publication number
AR062575A1
AR062575A1 ARP070103823A ARP070103823A AR062575A1 AR 062575 A1 AR062575 A1 AR 062575A1 AR P070103823 A ARP070103823 A AR P070103823A AR P070103823 A ARP070103823 A AR P070103823A AR 062575 A1 AR062575 A1 AR 062575A1
Authority
AR
Argentina
Prior art keywords
pro
igf
variant
pegylated
production
Prior art date
Application number
ARP070103823A
Other languages
English (en)
Inventor
Joerg Thomas Regula
Hendrik Knoetgen
Andreas Schaubmar
Hans-J Schoenfeld
Christian Schantz
Kart Lang
Friedrich Metzger
Frederike Hesse
Stephan Fischer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37667695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062575(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR062575A1 publication Critical patent/AR062575A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un método para la produccion de IGF-I o variante de IGF-l PEGilado en la lisina, y dicha variante comprende uno o dos aminoácido(s) seleccionados del grupo que consiste en lisina 27, 65 y/o 68 sustituidos independientemente por otro aminoácido polar, que se caracteriza por cultivar una célula huésped procariota que comprende un vector de expresion que contiene un ácido nucleico que codifica una proteína de fusion que comprende dicho IGF-I o variante de IGF-I unido en el extremo N-terminal al extremo C-terminal de un propéptido en el que dicho propéptido finaliza en el C-terminal con los aminoácidos -Y-Pro, en el que Y se selecciona del grupo que consiste en Pro, Pro-Ala, Pro-Gly, Pro-Thr, Ala-Pro, Gly-Pro, Thr-Pro, Arg-Pro, o Pro-Arg- Pro, recuperando y PEGilando dicha proteína de fusion, escindiendo dicha proteína de fusion PEGilada con la proteasa IgA, y recuperando dicho IGF-I o variante de IGF-I PEGilado. El IGF-I o variante de IGF-I PEGilado es util para el tratamiento de trastornos neurodegenerativos como la enfermedad de Alzheimer.
ARP070103823A 2006-08-31 2007-08-29 Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol AR062575A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06018170 2006-08-31

Publications (1)

Publication Number Publication Date
AR062575A1 true AR062575A1 (es) 2008-11-19

Family

ID=37667695

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103823A AR062575A1 (es) 2006-08-31 2007-08-29 Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol

Country Status (21)

Country Link
US (4) US7625996B2 (es)
EP (1) EP2059261B1 (es)
JP (1) JP5184532B2 (es)
KR (1) KR101106931B1 (es)
CN (1) CN101511390B (es)
AR (1) AR062575A1 (es)
AU (1) AU2007291502B2 (es)
BR (1) BRPI0715943A2 (es)
CA (1) CA2662062C (es)
CL (1) CL2007002502A1 (es)
CO (1) CO6251278A2 (es)
CR (1) CR10591A (es)
ES (1) ES2397660T3 (es)
IL (1) IL196736A (es)
MA (1) MA30660B1 (es)
MX (1) MX2009002011A (es)
NO (1) NO20090451L (es)
PE (1) PE20080912A1 (es)
RU (1) RU2009106118A (es)
TW (1) TW200819468A (es)
WO (1) WO2008025528A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP1994155B2 (en) 2006-02-13 2022-05-04 Daiichi Sankyo Company, Limited Polynucleotide and polypeptide sequences involved in the process of bone remodeling
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
MX2009001691A (es) 2006-08-31 2009-02-25 Hoffmann La Roche Metodo para produccion del factor de crecimiento i tipo insulina.
AU2009210570B2 (en) 2008-01-30 2014-11-20 Indiana University Research And Technology Corporation Ester-based insulin prodrugs
ES2388827T3 (es) * 2008-04-03 2012-10-19 F. Hoffmann-La Roche Ag Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares
JP2012512900A (ja) * 2008-12-19 2012-06-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション インスリン受容体に対して高い活性を示すｙｌ系インスリン様増殖因子
EP2376520B1 (en) 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
WO2010080609A1 (en) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
CN102740896B (zh) 2010-02-11 2014-08-27 霍夫曼-拉罗奇有限公司 Igf-i聚乙二醇缀合物
WO2011159895A2 (en) 2010-06-16 2011-12-22 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
JP5912112B2 (ja) 2010-06-24 2016-04-27 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ アミド系インスリンプロドラッグ
GB201012784D0 (en) 2010-07-29 2010-09-15 Ucb Pharma Sa Method
EP2793932B1 (en) 2011-12-20 2018-10-03 Indiana University Research and Technology Corporation Ctp-based insulin analogs for treatment of diabetes
EP2875051B1 (en) 2012-07-19 2019-02-20 Daiichi Sankyo Company, Limited Anti-siglec-15 antibodies
CN104981251B (zh) 2012-09-26 2018-03-20 印第安纳大学研究及科技有限公司 胰岛素类似物二聚体
KR20150131213A (ko) 2013-03-14 2015-11-24 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 인슐린-인크레틴 접합체들
WO2014205617A1 (en) * 2013-06-24 2014-12-31 Shandong University Lanthanide labeled peptide and use thereof
CA2926173A1 (en) 2013-10-02 2015-04-09 Novartis Ag Insulin-like growth factor mimetics for use in therapy
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
ES2822994T3 (es) 2014-09-24 2021-05-05 Univ Indiana Res & Tech Corp Conjugados de incretina-insulina
EP3197912B1 (en) 2014-09-24 2023-01-04 Indiana University Research & Technology Corporation Lipidated amide-based insulin prodrugs
JP7118508B2 (ja) * 2016-02-23 2022-08-16 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト 神経損傷を治療するペプチドベースの方法
BR112021011938A2 (pt) * 2018-12-19 2021-11-09 United Biomedical Inc Epítopos de célula t helper promíscuos artificiais como imunoestimuladores para imunógenos peptídicos sintéticos
EP3911668A1 (en) 2019-01-18 2021-11-24 The Regents of the University of Colorado, a body corporate Amphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207842A (en) 1983-04-25 1988-02-12 Chiron Corp Production of human insulin-like growth factor (igf) using cdna
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6235488B1 (en) 1988-09-29 2001-05-22 Agilent Technologies, Inc. Surface preparation for chemical-specific binding
EP0400472B1 (en) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
US6723699B1 (en) * 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
DE3924705A1 (de) 1989-07-26 1991-01-31 Boehringer Mannheim Gmbh Heterobifunktionelle verbindungen
US5158875A (en) 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5861373A (en) 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
EP0597033B1 (en) 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
JPH08506095A (ja) 1992-11-25 1996-07-02 アムジェン ボールダー インコーポレイテッド 改変インシュリン様成長因子
JPH10500693A (ja) 1994-05-24 1998-01-20 アムジエン・ブルダー・インコーポレーテツド 改変型インスリン様増殖因子
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CN1246891A (zh) 1997-02-06 2000-03-08 诺沃挪第克公司 添加和/或除去了连接基团的多肽－聚合物偶联物
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US20030204864A1 (en) * 2001-02-28 2003-10-30 Henry Daniell Pharmaceutical proteins, human therapeutics, human serum albumin, insulin, native cholera toxic b submitted on transgenic plastids
US6767892B1 (en) 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US7067485B2 (en) 1997-11-07 2006-06-27 Chiron Corporation IGF-I composition and its use
US6248546B1 (en) 1998-03-09 2001-06-19 Diagnostic Systems Laboratories, Inc. Assay of IGFBP complex
AU3764199A (en) 1998-04-29 1999-11-16 Genentech Inc. Spray dried formulations of igf-i
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
EP0972838B1 (en) 1998-07-15 2004-09-15 Roche Diagnostics GmbH Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
WO2000061177A1 (en) 1999-04-08 2000-10-19 Genentech, Inc. Composition based on oppositely-charged polypeptides
US6596849B1 (en) 1999-05-28 2003-07-22 Academia Sinica Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
DE60133271T2 (de) * 2000-05-16 2009-04-23 Genentech, Inc., South San Francisco Behandlung von knorpelerkrankungen
WO2001088149A1 (en) * 2000-05-16 2001-11-22 Center For Advanced Science And Technology Incubation, Ltd. Polypeptides cleaving telomeric repeats
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
US20040014652A1 (en) 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
AU2002211688A1 (en) 2000-10-13 2002-04-29 Chiron Corporation Method for treating ischemic events affecting the central nervous system
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
AU2002259281A1 (en) 2001-05-21 2002-12-03 Nektar Therapeutics Al, Corporation Antibodies specific for poly(ethylene glycol)
KR101162908B1 (ko) * 2002-12-26 2012-07-06 마운틴 뷰 파마슈티컬즈, 인크. 수용체-결합 활성이 보존된, 사이토카인, 케모카인,성장인자, 폴리펩티드 호르몬 및 이들의 길항제의 중합체접합체
EP1674113A1 (en) 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
JP4988599B2 (ja) 2005-01-07 2012-08-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｇｆ−１融合ポリペプチドおよびその治療的使用
EP1999149A4 (en) * 2006-03-28 2010-01-20 Biogen Idec Inc ANTI-IGF-1R ANTIBODIES AND USES THEREOF
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
ES2388827T3 (es) 2008-04-03 2012-10-19 F. Hoffmann-La Roche Ag Uso de variantes de IGF-I PEGiladas para el tratamiento de trastornos neuromusculares

Also Published As

Publication number Publication date
RU2009106118A (ru) 2010-10-10
CL2007002502A1 (es) 2008-05-30
NO20090451L (no) 2009-02-26
US20130065831A1 (en) 2013-03-14
CN101511390B (zh) 2013-04-24
JP5184532B2 (ja) 2013-04-17
PE20080912A1 (es) 2008-07-19
CA2662062A1 (en) 2008-03-06
TW200819468A (en) 2008-05-01
EP2059261A1 (en) 2009-05-20
MX2009002011A (es) 2009-03-05
CN101511390A (zh) 2009-08-19
CO6251278A2 (es) 2011-02-21
AU2007291502A1 (en) 2008-03-06
MA30660B1 (fr) 2009-08-03
US20080119409A1 (en) 2008-05-22
US20100035817A1 (en) 2010-02-11
US20100210547A1 (en) 2010-08-19
BRPI0715943A2 (pt) 2013-07-30
JP2010501192A (ja) 2010-01-21
WO2008025528A1 (en) 2008-03-06
AU2007291502B2 (en) 2012-05-31
CA2662062C (en) 2015-06-23
KR20090046875A (ko) 2009-05-11
IL196736A (en) 2013-10-31
US7625996B2 (en) 2009-12-01
IL196736A0 (en) 2009-11-18
US8476232B2 (en) 2013-07-02
CR10591A (es) 2009-04-03
EP2059261B1 (en) 2012-10-24
ES2397660T3 (es) 2013-03-08
KR101106931B1 (ko) 2012-01-25

Similar Documents

Publication Publication Date Title
AR062575A1 (es) Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina -1 y polietilenglicol
WO2008025527A8 (en) Method for the production of insulin-like growth factor-i
ES2633894T3 (es) Procedimiento para producir moléculas monoméricas y multiméricas y usos de las mismas
DK1874932T3 (da) Produktion af rekombinante proteiner ved autoproteolytisk spaltning af et fusionsprotein
ES2723774T3 (es) Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
AR078533A1 (es) Procedimiento para fabricar una toxina bacteriana por expresion periplasmica
AR071969A1 (es) Proteasa especifica de prolina identificada en el hongo penicillium chrysogenum
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
JP2017536835A5 (es)
ES2531402T3 (es) Colagenasa de fusión a la que se une una marca de afinidad, y método para producir la misma
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
Yang et al. Expression and purification of the antimicrobial peptide cecropin AD by fusion with cationic elastin-like polypeptides
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
AR065074A1 (es) Peptidos de senalizacion
ATE455125T1 (de) Tool für den transfer und die herstelung von proteinen mit dem pseudomonas-typ-iii- sekretionssystem
PE20020857A1 (es) Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras
CN101967493A (zh) 一种原核表达载体及其应用
Wang et al. A novel strategy for the preparation of codon-optimized truncated Ulp1 and its simplified application to cleavage the SUMO fusion protein
US20160122793A1 (en) Fusion Protease
NZ589806A (en) Variant hedgehog-interacting protein (hhip1) and methods and uses thereof
JP2020529845A5 (es)
WO2014057437A3 (fr) Procede de preparation de proteine c1q recombinante
PE32696A1 (es) Gen codificante y procedimiento de expresion de una nueva enzima: ftalil amidasa
DE602005025141D1 (de) In Zellen eindringende Peptide als Träger für Moleküle
Kong et al. The third helix of the murine Hoxc8 homeodomain facilitates protein transduction in mammalian cells

Legal Events

Date Code Title Description
FA Abandonment or withdrawal